PMID- 29661455
OWN - NLM
STAT- MEDLINE
DCOM- 20180828
LR  - 20211204
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 50
IP  - 3
DP  - 2018 Apr
TI  - Management of Juvenile Idiopathic Arthritis in ABO-incompatible Kidney 
      Transplantation: A Case Report.
PG  - 869-872
LID - S0041-1345(17)30976-4 [pii]
LID - 10.1016/j.transproceed.2017.12.052 [doi]
AB  - Biologic agents are a beneficial therapy for juvenile idiopathic arthritis (JIA). 
      However, there is a lack of evidence with regard to management of these agents 
      for JIA patients who undergo kidney transplantation (KTx). A 36-year-old woman 
      with JIA who was treated with tocilizumab targeting interleukin-6 (IL-6) receptor 
      underwent ABO-incompatible kidney transplantation (ABOi KTx). To prevent 
      over-immunosuppression, tocilizumab was discontinued before ABOi KTx. Rituximab, 
      tacrolimus, mycophenolate mofetil, everolimus, and methylprednisolone were used 
      for immunosuppression. Clinical remission of joint pain was maintained for over 3 
      years despite complete discontinuation of tocilizumab. Both serum IL-6 and 
      soluble IL-6 receptor levels were markedly decreased, suggesting that 
      multitargeted immunosuppression for ABOi KTx induced long-term clinical remission 
      of JIA through inhibition of the IL-6 pathway. However, levels of C-reactive 
      protein (CRP) and matrix metalloproteinase-3 (MMP-3) gradually increased 
      thereafter and abatacept was initiated to prevent joint deterioration. These 
      levels decreased without any adverse events. The patient's renal graft function 
      was well maintained.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Ishikawa, S
AU  - Ishikawa S
AD  - Division of Urology, Department of Regenerative and Transplant Medicine, Niigata 
      Graduate School of Medical and Dental Sciences, Niigata, Japan.
FAU - Tasaki, M
AU  - Tasaki M
AD  - Division of Urology, Department of Regenerative and Transplant Medicine, Niigata 
      Graduate School of Medical and Dental Sciences, Niigata, Japan. Electronic 
      address: masa1214@med.niigata-u.ne.jp.
FAU - Kuroda, T
AU  - Kuroda T
AD  - Division of Clinical Nephrology and Rheumatology, Graduate School of Medical and 
      Dental Sciences, Niigata University, Niigata, Japan.
FAU - Kobayashi, D
AU  - Kobayashi D
AD  - Division of Clinical Nephrology and Rheumatology, Graduate School of Medical and 
      Dental Sciences, Niigata University, Niigata, Japan.
FAU - Saito, K
AU  - Saito K
AD  - Division of Urology, Department of Regenerative and Transplant Medicine, Niigata 
      Graduate School of Medical and Dental Sciences, Niigata, Japan.
FAU - Nakagawa, Y
AU  - Nakagawa Y
AD  - Division of Urology, Department of Regenerative and Transplant Medicine, Niigata 
      Graduate School of Medical and Dental Sciences, Niigata, Japan.
FAU - Ikeda, M
AU  - Ikeda M
AD  - Division of Urology, Department of Regenerative and Transplant Medicine, Niigata 
      Graduate School of Medical and Dental Sciences, Niigata, Japan.
FAU - Takahashi, K
AU  - Takahashi K
AD  - Division of Urology, Department of Regenerative and Transplant Medicine, Niigata 
      Graduate School of Medical and Dental Sciences, Niigata, Japan.
FAU - Tomita, Y
AU  - Tomita Y
AD  - Division of Urology, Department of Regenerative and Transplant Medicine, Niigata 
      Graduate School of Medical and Dental Sciences, Niigata, Japan.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (ABO Blood-Group System)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Immunosuppressive Agents)
RN  - 4F4X42SYQ6 (Rituximab)
RN  - 7D0YB67S97 (Abatacept)
RN  - 9HW64Q8G6G (Everolimus)
RN  - I031V2H011 (tocilizumab)
RN  - WM0HAQ4WNM (Tacrolimus)
SB  - IM
MH  - ABO Blood-Group System
MH  - Abatacept/therapeutic use
MH  - Adult
MH  - Antibodies, Monoclonal, Humanized/therapeutic use
MH  - Arthritis, Juvenile/drug therapy/*immunology
MH  - Blood Group Incompatibility/*immunology
MH  - Everolimus/therapeutic use
MH  - Female
MH  - Humans
MH  - Immunosuppression Therapy/*methods
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Kidney Transplantation/*adverse effects
MH  - Postoperative Complications/drug therapy/*immunology
MH  - Rituximab/therapeutic use
MH  - Tacrolimus/therapeutic use
MH  - Transplants
EDAT- 2018/04/18 06:00
MHDA- 2018/08/29 06:00
CRDT- 2018/04/18 06:00
PHST- 2017/09/14 00:00 [received]
PHST- 2017/12/18 00:00 [accepted]
PHST- 2018/04/18 06:00 [entrez]
PHST- 2018/04/18 06:00 [pubmed]
PHST- 2018/08/29 06:00 [medline]
AID - S0041-1345(17)30976-4 [pii]
AID - 10.1016/j.transproceed.2017.12.052 [doi]
PST - ppublish
SO  - Transplant Proc. 2018 Apr;50(3):869-872. doi: 10.1016/j.transproceed.2017.12.052.